The Prostaglandin Biosynthesis Quandary
Fundamental physiological distinctions are now recognized for the structurally similar enzymes, COX-1 and COX-2. Constitutively expressed COX-1 is found in almost all of the tissues where it subserves diverse physiological functions. Basal expression of COX-2 is limited to the kidney, brain, and reproductive system 4 but can be ubiquitously upregulated in diverse tissues at sites of inflammation, an effect that is paramount in the progression of various pathologies. 6 The seemingly simplistic distinction between beneficial COX-1 and deleterious COX-2 led to the development of selective COX-2 inhibitors. Although these drugs successfully suppressed inflammation while minimizing the gastrointestinal complications of nonselective COX inhibitors, 7 cardiovascular complications attributed to disruption of the tightly regulated equilibrium of prostaglandin (PG) production in the blood vessel is less than ideal.
COX enzymes produce PGs that both prevent and promote vascular diseases. Under physiological conditions, COX catalysis relies on the COX and peroxidase functionalities of this enzyme. The COX domain catalyzes the conversion of arachidonic acid (AA) to PGG 2 , and the peroxidase domain catalyzes the reduction of PGG 2 to an unstable endoperoxide, PGH 2 . Via the action of specific downstream synthases, PGH 2 is converted to species including thromboxane A 2 (TxA 2 ), PGE 2 , and prostacyclin (PGI 2 ). Platelet-derived TxA 2 is a potent platelet activator and vasoconstrictor, 8 whereas PGE 2 is a proinflammatory molecule associated with atherosclerotic plaque destabilization. 9 Conversely, PGI 2 , the major product of vascular endothelial cells, is a powerful vasodilator and inhibitor of platelet activation and adhesion 10 ( Figure  2 ). The benefit of low-dose aspirin in reducing cardiovascular disease results from selective acetylation of COX-1 and blockade of TxA 2 formation by platelets while retaining endothelial PGI 2 production. 11 COX-2 provides a crucial source of PGI 2 in humans; thus, a reduction in PGI 2 production, coupled with unchecked COX-1-dependent plateletderived TxA 2 , was inferred to mediate adverse cardiovascular events. 12 If this is indeed the case, would a selective COX-2 inhibitor combined with a platelet-selective low dose of aspirin provide protection against these adverse effects?
Current evidence indicates that cardiovascular risk is not only associated with selective COX-2 inhibitors but also with long-term treatment with traditional NSAIDs. 13 Endothelial COX-1 from normal vessels may be more readily inhibited by NSAIDs than platelet COX-1, preventing endothelial PGI 2 formation but not platelet-derived TxA 2 . 14 It may be that the apparent selectivity of a given COX inhibitor is determined by a target cell's peroxide content and arachidonate availability, rather than selectivity for a particular isoform. 14 Because PGI 2 is vasoprotective, it is not surprising that COX-2 induction can generate compensatory PGI 2 at sites of vascular injury. Indeed, COX-2 is highly expressed in atherosclerotic lesions in animal models and humans. 15, 16 However, an increase in COX-2 expression also results in increased production of proinflammatory PGs, such as PGE 2 , which stimulate matrix metalloproteinase expression and contribute to atherosclerotic plaque rupture. 17 Accordingly, selective COX-2 inhibition in low-density lipoprotein receptor-deficient mice was found to diminish aortic atherogenesis. 18 Furthermore, a naturally occurring polymorphism in the COX-2 promoter that results in decreased COX-2 expression has been associated with a reduced incidence of cardiovascular events in humans. 19 Therefore, a global reduction in COX-2-derived PGs at sites of injury may have limited benefit, and the quest for a more focused interference, eg, selective targeting of individual PG receptor subtypes, may be more desirable.
Despite sharing a common agonist, each of the 4 PGE 2 receptors (EP1 to EP4) use multiple signaling pathways to elicit diverse and opposing physiological effects in the cardiovascular system. For example, PGE 2 receptor subtypes differentially regulate metalloproteinases and play a pivotal role in the regulation of plaque stability. Genetic silencing of EP4 expression or administration of a selective EP4 antagonist (ONO-AE3-208) was shown to significantly reduce COX-2-dependent metalloproteinase expression in macrophages. 20 On the other hand, studies with EP3-deficient mice demonstrate that PGE 2 facilitates arterial thrombosis and mechanical plaque rupture via EP3 activation. 21 In addition to influences on plaque stability, PGE 2 has been shown to play differential roles in the regulation of vascular smooth muscle tone and blood pressure. 22 For example, EP1 and EP3 are associated with vasoconstriction, whereas EP2 and EP4 promote vasodilation 22 (Figure 1) . Recent findings have shown that administration of the EP1 receptor antagonist SC51322, or selective genetic disruption of the EP1 receptor, reduces blood pressure and is, thus, a potential target for the treatment of hypertension. 23 The diverse nature of PGE 2 -mediated effects highlights the need for selective pharmacological targeting of specific inflammatory PG signaling pathways. Structure-function studies of enzymes and receptors relevant to PG signaling pathways, coupled with the availability of high-throughput screening methods, should drive the development of novel compounds that selectively target specific PGs with diminished adverse effects, relative to more broadly acting COX inhibitors (Figure 1 ).
Redressing the Balance of COX Products With Alternative Substrates
The preferred substrate for COX is AA (an omega-6 fatty acid), although eicosapentaenoic acid (EPA; an omega-3 fatty acid enriched in dietary fish oils) also serves as a substrate. Of note, AA-derived PGs contribute to a stronger inflammatory response than their EPA-derived counterparts. As such, omega-6 fatty acid-rich Western diets are believed to contribute to the genesis of vasoinflammatory disorders, including atherosclerosis and diabetes. AA and EPA can also undergo nonenzymatic oxidation in vivo to generate vasoactive hydroperoxides, epoxides, and isoprostanes. 24 In fact, quantification of urinary isoprostane has served as a marker of oxidative stress and lipid peroxidation in association with various inflammatory conditions. 25 Interestingly, dietary supplementation of EPA in rodents increased noninflammatory EPA-derived isoprostanes while reducing proinflammatory AA-derived isoprostanes. 26 EPA-derived mediators may also have decreased inflammatory potential, because EPA-derived PGE 3 induced COX-2 to a significantly lesser extent than AA-derived PGE 2 . 27 Furthermore, rabbits receiving omega-3 fatty acids experienced a significant reduction in infarct size resulting from ischemia-reperfusion injury. 28 Together, these studies indicate that alternative COX substrates yield different PG products, and this knowledge may be exploitable for future diet-based suppression of inflammation.
The differential metabolism of EPA and AA by COX enzymes can be explained biochemically by the activating peroxide concentration requirement for the enzyme. 29 Although COX-2 readily metabolizes EPA, COX-1 does so poorly. Notwithstanding, in hydroperoxide-rich cells such as platelets, EPA is efficiently metabolized by COX-1 to TxA 3 , an inactive thromboxane receptor ligand. 30 Therefore, increased EPA availability relative to AA can result in decreased formation of active COX-1-derived thromboxanes in platelets; conceivably, dietary EPA can provide an alternative to aspirin for decreasing thrombogenesis while avoiding gastrointestinal afflictions.
Investigations of targets that involve non-COX pathways of AA metabolism are also of interest. In fact, other AAmetabolizing enzymes, such as LOXs and cytochrome P450s, each producing lipid mediators with a variety of biological consequences in inflammatory diseases, may indirectly modulate COX and PG synthesis. Administration of NSAIDs was found to shift AA flow from COXs to the cytochrome P450 pathway resulting in increased accumulation of antiinflammatory epoxides. 31 Alternatively, 12-LOX metabolites, such as 12-hydroxyeicosatetraenoic acid, that are inflammatory can exert a regulatory role on COX-2 gene transcription and PG production. 32 Interestingly, exogenous administration of anti-inflammatory epoxides or inhibition of soluble epoxide hydrolase, the enzyme that hydrolyzes anti-inflammatory epoxides to the corresponding diols, is anti-inflammatory in a variety of disease models. 31, 33 Therefore, combination therapy with soluble epoxide hydrolase inhibitors and NSAIDs (at a reduced dose) promises the benefit of alleviating pain and inflammation while simultaneously reducing undesired adverse effects associated with NSAIDs. 31 
Targeting Oxidative Stress and Vascular Dysfunction Endothelial Dysfunction
Endothelial dysfunction is characterized by impaired endothelium-dependent relaxation in association with dysregulation of cell signaling pathways, alterations in prothrombotic/antithrombotic factor activities and increased cell permeability. Importantly, many of these phenotypic changes have been linked to diminished bioavailability of endothelium-derived ⅐ NO. Endothelial NO synthase (NOS; eNOS) provides the essential source of vascular ⅐ NO for regulating blood flow, oxygen delivery, and vascular tone, although inducible NOS (iNOS) and neuronal NOS may contribute under certain conditions. 34 In accord with the fundamental importance of ⅐ NO in maintaining vascular homeostasis, endothelial dysfunction has been implicated in the pathogenesis of chronic vascular disorders including diabetes, hypertension, and atherosclerosis. 35, 36 Under normal physiological conditions, cellular respiration and metabolism produce low levels of reactive oxygen species (ROS), including superoxide anion (O 2 ⅐Ϫ ), hydroxyl radical, and peroxyl radicals. Key sources of vascular O 2 ⅐Ϫ include the mitochondrial electron transport chain, LOXs, COXs, xanthine oxidases, and reduced nicotinamide-adenine dinucleotide phosphate oxidases. 37 Cells are equipped with antioxidant defense mechanisms that function to suppress cellular ROS levels. However, inflammatory cells can generate bursts of oxidants that defend the host against invading organisms and overwhelm antioxidant defense systems leading to pathophysiological conditions associated with vascular ⅐ NO insufficiency. 38 Prevention of ROS-dependent losses in ⅐ NO bioavailability has emerged as a therapeutic goal for the management of many cardiovascular disorders.
eNOS Recoupling Therapy
Increased production of ROS can disrupt the tightly regulated eNOS catalytic machinery in endothelial cells, leading to preferential O 2 ⅐Ϫ generation in lieu of ⅐ NO, a phenomenon termed "eNOS uncoupling." 3 Production of ⅐ NO in the setting of O 2 ⅐Ϫ excess favors the formation of peroxynitrite (ONOO Ϫ ), a cytotoxic species that can profoundly override protection afforded by superoxide dismutases 3 and inhibit glutathione peroxidase. 39 ROS can also deplete antioxidants like vitamin C and glutathione that serve to maintain the cellular redox status. 3 Although antioxidant deficiencies seem to contribute to the impairment of vascular function, 40 antioxidant therapies are generally ineffective in limiting the pathogenesis of these conditions. Explanations for this paradox have focused on the complexity of oxidative reactions and the differential subcellular localization associated with the synthesis and accessibility of pro-oxidant and antioxidant species. 41 Recently, more targeted approaches have been used to enhance NOS coupling efficiency, such as treatment with tetrahydrobiopterin (BH4), an essential cofactor of NOS. 42, 43 Treatment with BH4 has been shown to acutely reverse impaired endothelium-dependent vasodilatation associated with hypercholesterolemia and diabetes. 44, 45 Similarly, gene therapy to increase expression of GTP-cyclohydrolase I, the rate-limiting enzyme in BH4 synthesis, can reverse endothelial dysfunction and reduce atherosclerotic lesion formation in atherogenic mice that overexpress eNOS. Paradoxically, an increase in eNOS expression without a commensurate increase in BH4 cofactor availability enhances oxidative stress. 41 In a recent study, atherosclerotic patients receiving a low dose of folic acid, which enhances BH4 bioavailability, were found to have improved eNOS activity and attenuated vascular dysfunction. The vascular benefits of folate were highly dependent on vascular levels of the metabolite 5-methyltetrahydrofolate, 46 which efficiently scavenges ONOO Ϫ and protects BH4 from oxidative inactivation. 47 ⅐ NO bioavailability can potentially be enhanced by increasing L-arginine availability. Although a number of small case studies have suggested a beneficial effect of arginine supplementation in animals and humans with atherosclerosis, 48, 49 other studies have challenged these findings. 50 One potential avenue of therapy involves modulation of arginase. Enhanced expression and activation of arginase, the enzyme responsible for the conversion of arginine to L-ornithine, has been implicated in endothelial dysfunction in animal models of hypertension and atherosclerosis. 51, 52 Accordingly, if arginase inhibition could be achieved while preserving the urea cycle, some patients may benefit.
Thus, in the process of evaluating new approaches for the treatment of endothelial dysfunction, a newfound appreciation for uncoupled eNOS as a significant therapeutic target has emerged. We anticipate positive outcomes of eNOS recoupling therapies from definitive clinical trials for conditions associated with endothelial dysfunction.
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Inducible NOS: Pathological or Beneficial?
iNOS is upregulated in cells exposed to a variety of proinflammatory insults. Excessive production of iNOS-derived ⅐ NO can serve as a compensatory mechanism to replenish anti-inflammatory ⅐ NO in the face of eNOS uncoupling or as a pathological mechanism promoting inflammation via the formation of higher oxides of nitrogen (NO x 53 Results predominantly indicate that low levels of ⅐ NO produced by eNOS are beneficial, whereas continuous production of ⅐ NO by iNOS is cytostatic. This paradigm seems to extend to vascular inflammatory conditions, such as atherogenesis 54 and immunoactivated vascular smooth muscle cells. 55 Interestingly, EPA, known for its cardiovascular benefits (discussed earlier), exerts its anti-inflammatory beneficial actions, in part, by enhanced ⅐ NO synthesis. Administration of EPA stimulated ⅐ NO production from eNOS and improved cardiac function in diabetic rats. 56 EPA was also shown to promote the synthesis of ⅐ NO and reduce myocardial infarct size in rabbit hearts 57 and to significantly suppress iNOS gene expression in hypertrophied cardiomyocytes. 58 Possible mechanisms of iNOS downregulation by EPA may include activation of calcium channel-mediated signaling pathways 57 and peroxisome proliferator-activated receptor-retinoid X receptor pathways that suppress nuclear factor B-induced iNOS gene expression. 59 Inflammatory stimuli trigger the expression of COX-2, iNOS, and nitration of proteins that colocalize in atherosclerotic lesions, accumulating mainly in macrophages. 60 Recently, a direct physical interaction of iNOS and COX-2 was demonstrated in macrophages, engendering specific nitrosylation of COX-2 on a defined cysteine residue that results in enhanced catalytic activity. 61 Recognition of the direct interaction between iNOS and COX-2 has stimulated interest in pharmacological manipulations of iNOS that may limit inflammatory PG synthesis as an alternative to selective COX-2 inhibitors. Mounting evidence of COX nitration provides another example of how ⅐ NO-dependent modifications can alter the COX structure and function, reaffirming the mutually interactive nature of the NOS/COX systems.
Is Posttranslational Inhibition of COX by NO x Biologically Relevant?
The complex nature of ⅐ NO chemistry, its related modifications of biomolecules, and attendant cellular responses, create a challenge for defining the role of ⅐ NO in physiological and pathophysiological processes. This complexity involves the following: (1) identification of the relevant ⅐ NO-derived species (NO x ), eg, ⅐ NO itself, nitrogen dioxide, ONOO Ϫ , and nitrosoperoxocarbonate 3 ; (2) determination of the identity of the protein(s) subject to modification by NO x ; (3) identification of the nature and sites of these modifications; and (4) elucidation of the consequences of modification for protein functions. The study of NO x -dependent modifications of COX enzymes have resulted in inconsistent reports of activation 62, 63 and inhibition. 64 -66 These studies have described a variety of COX modifications, including heme oxidation, tyrosine (Tyr) nitration, and cysteine nitrosylation, all of which likely underlie the divergent actions of NO x species on COX enzyme activities. NO x -initiated modifications of COX can elicit 2 alternative outcomes: activation of COX (eg, by heme oxidation and cysteine S-nitrosylation), favoring prostacyclin (PGI 2 ) production and maintenance of vessel homeostasis, and inhibition of COX (eg, by Tyr nitration) suppressing PGI 2 production, thus favoring TxA 2 synthesis and vascular disease. Although the functional changes in COX that are elicited by these alternative NO x -induced modifications may be clear, conditions under which a particular reaction predominates remains undefined, and the extent to which these modifications determine COX activity in vivo remains to be established. 67 COX Nitration: A Pathological Modification or Nature's "Aspirin"?
Essential criteria must be realized for a particular posttranslational protein modification to be considered physiologically relevant. Is it molecularly selective, reversible, and/or extensive? Does it significantly alter protein functions?
S-Nitrosylation of proteins, the covalent addition of ⅐ NO to particular cysteine residues, is now recognized as a physiologically important posttranslational modification for the control of numerous proteins in the cardiovascular system. 68, 69 However, Tyr nitration of proteins has not garnered the same attention. Indeed, Tyr nitration is often considered to be a toxic and irreversible modification that occurs in the setting of extreme oxidative stress, commonly resulting in a loss of protein function, disruption of cell signaling cascades, and/or accelerated protein degradation. 70 However, intriguing studies describe an organ-specific and regulatory enzymatic activity that can remove protein Tyr nitration via the action of an inferred class of "denitrase" enzymes. [71] [72] [73] Thus, it is possible that nitration of Tyr residues plays a moment-tomoment regulatory role in vasoinflammatory processes and, potentially, their resolution (Figure 2 ). Figure 2 . Host defense mechanisms may include regulated processes involving organ-and site-specific nitration of proteins that serve to maintain homeostatic levels of inflammatory mediators.
Recent reports have described a pivotal role for protein transition metal ions in selectively targeting nitration by ONOO Ϫ to specific Tyr residues. This phenomenon has been documented for ferric hemoglobin, cytochrome P450, prostacyclin synthase, and COX-1 16,66,74 -76 and occurs by a pathway that allows for the decay of ONOO Ϫ to an efficient nitrating species, nitrogen dioxide, formed in close proximity to the targeted Tyr. For prostacyclin synthase, an enzyme downstream of COX, a hemeiron selectively targets nitration to Tyr430, resulting in a loss of catalytic activity. 75 For COX-1, nitration is selectively targeted to Tyr385 resulting in inactivation; notably, whereas COX-1 nitration occurs in the absence of heme, this is not on Tyr385 and has no detectable impact on COX function. 16, 66 These studies highlight the importance of the metal-porphyrin group in hemoproteins for selective targeting of Tyr nitration by ONOO Ϫ . 66, 75 Importantly, nitrated COX-1 has been identified in mouse and human atherosclerotic lesional tissue. 16, 65 Because ONOO Ϫ is a short-lived species that acts locally, selective nitration of COX-1 by ONOO Ϫ can be viewed as nature's aspirin, providing a mechanism for limiting synthesis of inflammatory PGs at focal sites of inflammation. Much like the use of isoform-selective COX inhibitors, selective targeting of nitration to sites of inflammation may serve to spatially restrict PG synthesis and promote the resolution of inflammation (Figure 2) .
Currently, it is difficult to estimate the physiological/ pathophysiological importance of COX inhibition by nitration. However, given that PGs can have opposing actions, it is reasonable to assume that selective and organ-specific COX nitration can be beneficial at sites where PGs are disease promoting. Alternatively, COX denitration may assist in resolving inflammation in organs where the loss of PGs contributes to disease progression.
Future Therapeutic Potentials for Hybrid COX Inhibitors
Appreciation of the fact that the heme peroxidase site in COX can catalyze chemical reactions independent of AA metabolism has triggered a great deal of interest in the development of agents with the dual capacity to inhibit both the COX and peroxidase reactions. 77 In addition to heme oxidation by ROS and NO x species, the COX peroxidase site can oxidize electron donor compounds such as polycyclic aromatic hydrocarbons from cigarette smoke. The latter reaction can lead to polar, highly reactive, and strongly mutagenic intermediates that attack DNA and proteins. 78 Such intermediates can exacerbate inflammation and alter PG biosynthesis by inducing COX-2 expression at sites of vascular injury, 79 activating nuclear factor B and activator protein-1 80 and suppressing prostacyclin synthase gene expression. 81 Dual inhibitors of peroxidase and COX activities would dampen a currently untargeted COX function (peroxidase), such new drugs that await evaluation. (Figure 1 ). Clinical studies in osteoarthritic patients with one such agent, nitronaproxen, were favorable, particularly in hypertensive patients where a potent anti-inflammatory response accompanied treatment. 83 Development of COX-inhibiting ⅐ NO donators for a wide variety of NSAIDs, 84 including aspirin (NCX 4016; ⅐ NO-donating aspirin) for potential therapy of cardiovascular diseases, is currently underway. 85 Thus, optimal anti-inflammatory therapy with reduced risk may start with what we know is effective, ie, conventional COX-inhibiting NSAIDs, fine tuned for ⅐ NO delivery.
Perspectives
It is well recognized that the protection against atherosclerosis resides in the endothelium. However, more complete molecular details for how the endothelium exerts its vasoprotective action are needed, as is a clarification of the interactions of vascular mediators and oxidant stress that promote vascular damage. Ongoing investigations of the cross-talk between the COX and the ⅐ NO pathway have provided new possibilities for the regulation of PG production. As the complex chemistry between NO x and its protein targets is being increasingly defined, there is a growing appreciation that outcomes of this chemistry are dependent on the intracellular milieu, which will impact on disease progression. Harnessing knowledge that emerges from studies that define biologically relevant interactions of ⅐ NO and COX is expected to provide novel insights for the therapy of vasoinflammatory conditions. Currently, the development of new agents that target specific proinflammatory PGs, rather than COX itself, and the development of hybrid COX inhibitors that offer safer anti-inflammatory actions, represent promising new directions for pharmacotherapy of chronic cardiovascular disease. 
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